Linklaters advised Genfit, a biotech company listed on Euronext Paris, on a capital increase by private placement realised on 20 June 2014.

The private placement was entirely placed with leading international investors, with the majority coming from the US, for an amount of 49.7 million Euro. The settlement-delivery of the new shares took place on 27 June 2014.

As the capital increase represents less than 10% of Genfit’s outstanding share capital, no prospectus has been established for the purpose of the listing of the shares on Euronext Paris.

This private placement follows the direct listing of Genfit’s shares on the Euronext Paris regulated market on 15 April 2014, where Linklaters acted as counsel to the company.

The transaction was conducted by the Paris Capital Markets team composed of Bertrand Sénéchal, partner and Marie Gautier.